Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristian Hylleberg Christensen

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Journal of the American Heart Association|December 24, 2024
Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1,3-Butanediol in Patients With Heart Failure With Reduced Ejection FractionHalvor Guldbrandsen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
Platelets|November 20, 2013
Rapid evaluation of platelet function using the Multiplate® AnalyzerMorten Würtz, Anne-Mette Hvas, Kristian Hylleberg Christensen, et al.
Circulation. Heart Failure|December 24, 2024
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection FractionKristoffer Berg-Hansen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
JACC. Heart Failure|July 15, 2023
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock: A Randomized, Controlled, Double-Blind TrialKristoffer Berg-Hansen, Kristian Hylleberg Christensen, Nigopan Gopalasingam, et al.
Journal of the American Heart Association|June 10, 2023
Stimulation of the Hydroxycarboxylic Acid Receptor 2 With the Ketone Body 3-Hydroxybutyrate and Niacin in Patients With Chronic Heart Failure: Hemodynamic and Metabolic EffectsNigopan Gopalasingam, Kristian Hylleberg Christensen, Kristoffer Berg Hansen, et al.
Circulation|March 27, 2024
Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind TrialKristoffer Berg-Hansen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
Circulation|August 20, 2024
Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection FractionNigopan Gopalasingam, Kristoffer Berg-Hansen, Kristian Hylleberg Christensen, et al.
ESC Heart Failure|January 10, 2024
Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fractionKristian Hylleberg Christensen, Roni R Nielsen, Morten Schou, et al.
Journal of the American Heart Association|May 15, 2023
Hemodynamic Effects of Ketone Bodies in Patients With Pulmonary HypertensionRoni Nielsen, Kristian Hylleberg Christensen, Nigopan Gopalasingam, et al.
Journal of the American Heart Association|April 2, 2024
Enantiomer-Specific Cardiovascular Effects of the Ketone Body 3-HydroxybutyrateNigopan Gopalasingam, Niels Moeslund, Kristian Hylleberg Christensen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Journal of the American Heart Association|December 24, 2024
Cardiovascular and Metabolic Effects of Modulating Circulating Ketone Bodies With 1,3-Butanediol in Patients With Heart Failure With Reduced Ejection FractionHalvor Guldbrandsen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
Platelets|November 20, 2013
Rapid evaluation of platelet function using the Multiplate® AnalyzerMorten Würtz, Anne-Mette Hvas, Kristian Hylleberg Christensen, et al.
Circulation. Heart Failure|December 24, 2024
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection FractionKristoffer Berg-Hansen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
JACC. Heart Failure|July 15, 2023
Beneficial Effects of Ketone Ester in Patients With Cardiogenic Shock: A Randomized, Controlled, Double-Blind TrialKristoffer Berg-Hansen, Kristian Hylleberg Christensen, Nigopan Gopalasingam, et al.
Journal of the American Heart Association|June 10, 2023
Stimulation of the Hydroxycarboxylic Acid Receptor 2 With the Ketone Body 3-Hydroxybutyrate and Niacin in Patients With Chronic Heart Failure: Hemodynamic and Metabolic EffectsNigopan Gopalasingam, Kristian Hylleberg Christensen, Kristoffer Berg Hansen, et al.
Circulation|March 27, 2024
Cardiovascular Effects of Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction: A Randomized, Controlled, Double-Blind TrialKristoffer Berg-Hansen, Nigopan Gopalasingam, Kristian Hylleberg Christensen, et al.
Circulation|August 20, 2024
Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection FractionNigopan Gopalasingam, Kristoffer Berg-Hansen, Kristian Hylleberg Christensen, et al.
ESC Heart Failure|January 10, 2024
Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fractionKristian Hylleberg Christensen, Roni R Nielsen, Morten Schou, et al.
Journal of the American Heart Association|May 15, 2023
Hemodynamic Effects of Ketone Bodies in Patients With Pulmonary HypertensionRoni Nielsen, Kristian Hylleberg Christensen, Nigopan Gopalasingam, et al.
Journal of the American Heart Association|April 2, 2024
Enantiomer-Specific Cardiovascular Effects of the Ketone Body 3-HydroxybutyrateNigopan Gopalasingam, Niels Moeslund, Kristian Hylleberg Christensen, et al.
Pageof 1